{"id":4879,"date":"2019-10-09T12:01:05","date_gmt":"2019-10-09T10:01:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/"},"modified":"2019-10-09T12:01:05","modified_gmt":"2019-10-09T10:01:05","slug":"calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/","title":{"rendered":"Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–#biotech<\/a>—Calidi Biotherapeutics, Inc.<\/a> (\u201cCalidi\u201d), a clinical\u2010stage biotechnology company at the forefront of oncolytic virus-based<\/a> immunotherapies for cancer, today announced the appointment of seasoned biotech executive, George Ng, Partner of PENG Life Science Ventures. His extensive background includes co-founding and leading the efforts of a pharmaceutical company from pre-clinical to clinical to New Drug Application (NDA) submission to commercialization and subsequent sale of the company. In the process, he raised more than $140 million in non-dilutive funding to commercialize its FDA-approved pain medication. Calidi believes Mr. Ng\u2019s experience will help to accelerate the growth of the company and its proprietary and novel cell-based oncolytic virus delivery platform.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are honored to have George Ng join our board of directors. He is a recognized leader in the development, operation, and growth of biotech organizations worldwide. His contributions have played a significant role in the development and commercialization of multiple drugs across several therapeutic areas,\u201d said Allan J. Camaisa<\/a>, CEO and Chairman of Calidi Biotherapeutics. \u201cWe look forward to fully utilizing his experience as we head into Phase 2 clinical trials. We think his sincere approach to leading organizations will be a fantastic fit for the Calidi Biotherapeutics team.\u201d\n<\/p>\n

\nCalidi Biotherapeutics\u2019s proprietary technology platform has shown to significantly potentiate oncolytic virotherapy through a cell-based delivery system. In their first-in-human study in 26 patients with advanced metastatic cancer, Calidi demonstrated excellent safety and initial signals of efficacy after a single treatment administration. Following discussions with the Food and Drug Administration (FDA) Calidi is preparing an Investigational New Drug (IND) application to commence new Phase 1b\/2 clinical trials for their leading product candidate in patients with melanoma and other solid tumors.\n<\/p>\n

\n\u201cI am excited to join Calidi Biotherapeutics on their mission to treat, and hopefully cure difficult-to-treat cancer types,\u201d said George Ng, newly appointed board member of Calidi Biotherapeutics. \u201cCalidi is primed and ready to take the industry by storm. It is exciting to see the advances they have made in overcoming the hurdle of oncolytic viruses being eliminated by the patient\u2019s immune system.\u201d\n<\/p>\n

\nPreviously Mr. Ng was the President, Managing Director, Chief Administrative Officer, Corporate Secretary, Chief Legal Officer, General Counsel, Chief Compliance Officer and Chief Intellectual Property Counsel, with multiple publicly-traded and private, global biotechnology and pharmaceutical companies, including BioDelivery Sciences International, Inc. (NASDAQ: BDSI), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and Alpharma, Inc. (now, a part of Pfizer Inc.). In these roles, Mr. Ng helped lead the commercialization efforts and launches of multiple pharmaceutical drug products. During his early years, Mr. Ng was in private practice, as a partner in two AMLAW-200 law firms, where he held various leadership roles and helped establish a life science practice group for one of these firms.\n<\/p>\n

\nAmong his multiple awards and commendations, Mr. Ng was a recipient of the 2015 Outstanding 50 Asian Americans in Business Award, past recipient of M&A Advisor\u2019s Top 40 Under 40 Award (in 2012) and nominee for the Orange County Business Journal\u2019s Inaugural General Counsel Awards (in 2010); and, in 2010, MDB Capital recognized Mr. Ng (and the company where he led the intellectual property efforts) for its Best and Brightest Award and as an Astrum Award nominee for a pharmaceutical patent portfolio that he managed and developed. Mr. Ng earned a Juris Doctor (J.D.) degree in law from the University of Notre Dame School of Law and a Bachelor of Arts and Sciences (B.A.S.) dual degree in Biochemistry & Economics from the University of California, Davis.\n<\/p>\n

\nAbout Calidi Biotherapeutics
\n
<\/b>Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery of oncolytic viruses for targeted therapy against difficult to treat cancers. Calidi Biotherapeutics is advancing a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications. In addition, our team is developing a universal cell delivery system to house, protect, and potentiate any oncolytic viruses currently in development which can potentially enhance efficacy and improve patient safety. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com<\/a>.\n<\/p>\n

\nRelated Links
\n
<\/b>http:\/\/www.calidibio.com<\/a>\n<\/p>\n

\nForward Looking Statement:
\n
<\/b>Some of the statements in this press release may be forward-looking statements that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management\u2019s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company\u2019s control. Calidi Biotherapeutics does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Calidi Biotherapetucs and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and\/or statements in this press release or for any related damages.\n<\/p>\n

\"\"<\/span><\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:<\/b>
Stephen Thesing
\n
Senior Vice President, Corporate Development & Operations
\n
ir@calidibio.com<\/a><\/p>\n

Contact:<\/b>
Aimee Eucce
\n
aeucce@calidibio.com<\/a>
Calidi Biotherapeutics, Inc.\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–#biotech—Calidi Biotherapeutics, Inc. (\u201cCalidi\u201d), a clinical\u2010stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, George Ng, Partner of PENG Life Science Ventures. His extensive background includes co-founding and leading the efforts of a pharmaceutical company from pre-clinical to clinical to New Drug … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-4879","6":"format-standard","7":"category-allgemein"},"yoast_head":"\nCalidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–#biotech—Calidi Biotherapeutics, Inc. (\u201cCalidi\u201d), a clinical\u2010stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, George Ng, Partner of PENG Life Science Ventures. His extensive background includes co-founding and leading the efforts of a pharmaceutical company from pre-clinical to clinical to New Drug ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-09T10:01:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20191009005236\/en\/748705\/21\/CalidiBiotherapeutics-Logo%402x.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors\",\"datePublished\":\"2019-10-09T10:01:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\\\/\"},\"wordCount\":884,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005236\\\/en\\\/748705\\\/21\\\/CalidiBiotherapeutics-Logo%402x.jpg\",\"articleSection\":[\"Allgemein\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\\\/\",\"name\":\"Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005236\\\/en\\\/748705\\\/21\\\/CalidiBiotherapeutics-Logo%402x.jpg\",\"datePublished\":\"2019-10-09T10:01:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005236\\\/en\\\/748705\\\/21\\\/CalidiBiotherapeutics-Logo%402x.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005236\\\/en\\\/748705\\\/21\\\/CalidiBiotherapeutics-Logo%402x.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–#biotech—Calidi Biotherapeutics, Inc. (\u201cCalidi\u201d), a clinical\u2010stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, George Ng, Partner of PENG Life Science Ventures. His extensive background includes co-founding and leading the efforts of a pharmaceutical company from pre-clinical to clinical to New Drug ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/","og_site_name":"Pharma Trend","article_published_time":"2019-10-09T10:01:05+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20191009005236\/en\/748705\/21\/CalidiBiotherapeutics-Logo%402x.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors","datePublished":"2019-10-09T10:01:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/"},"wordCount":884,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20191009005236\/en\/748705\/21\/CalidiBiotherapeutics-Logo%402x.jpg","articleSection":["Allgemein"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/","url":"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/","name":"Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20191009005236\/en\/748705\/21\/CalidiBiotherapeutics-Logo%402x.jpg","datePublished":"2019-10-09T10:01:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20191009005236\/en\/748705\/21\/CalidiBiotherapeutics-Logo%402x.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20191009005236\/en\/748705\/21\/CalidiBiotherapeutics-Logo%402x.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/calidi-biotherapeutics-announces-appointment-of-seasoned-biotech-executive-george-ng-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/4879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=4879"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/4879\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=4879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=4879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=4879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}